Physiologically based pharmacokinetic modeling to assess metabolic drug–drug interaction risks and inform the drug label for fedratinib

被引：0
|
作者：
Fan Wu
Gopal Krishna
Sekhar Surapaneni
机构：
[1] Bristol Myers Squibb,Nonclinical Research and Development
[2] Bristol Myers Squibb,Clinical Pharmacology
来源：
Cancer Chemotherapy and Pharmacology | 2020年 / 86卷
关键词：
Drug–drug interaction; PBPK; Metabolic inhibition; Simcyp; Fedratinib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：461 / 473
页数：12
相关论文
共 50 条
  • [21] PROSPECTIVE APPLICATION OF PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODELING TO INFORM THE DESIGN OF A CLINICAL DRUG-DRUG INTERACTION (DDI) STUDY: CASE STUDY OF MEZIGDOMIDE
    Burnett, J.
    Sychterz, C.
    Zhu, Y.
    Shakeel, F.
    Dingley, K.
    Chen, W.
    Rajadhyaksha, P.
    Shahane, A.
    Wang, X.
    Gaohua, L.
    Lamba, M.
    Gaudy, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S108 - S108
  • [22] Physiologically based pharmacokinetic modeling of imatinib and N-desmethyl imatinib for drug-drug interaction predictions
    Loer, Helena Leonie Hanae
    Kovar, Christina
    Ruedesheim, Simeon
    Marok, Fatima Zahra
    Fuhr, Laura Maria
    Selzer, Dominik
    Schwab, Matthias
    Lehr, Thorsten
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2024, 13 (06): : 926 - 940
  • [23] PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING OF FIMASARTAN, AMLODIPINE, AND HYDROCHLOROTHIAZIDE FOR INVESTIGATION OF DRUG-DRUG INTERACTION POTENTIALS.
    Rhee, S. -J.
    Lee, S.
    Kim, E.
    Lee, H.
    Yu, K. -S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 : S47 - S48
  • [24] A physiologically based pharmacokinetic/pharmacodynamic modeling approach for drug-drug interaction evaluation of warfarin enantiomers with sorafenib
    Wang, Ziteng
    Xiang, Xiaoqiang
    Liu, Shuaibing
    Tang, Zhijia
    Sun, Hong
    Parvez, Masud
    Ghim, Jong-Lyul
    Shin, Jae-Gook
    Cai, Weimin
    DRUG METABOLISM AND PHARMACOKINETICS, 2021, 39
  • [25] Evaluation of the drug-drug interaction potential of brigatinib using a physiologically-based pharmacokinetic modeling approach
    Hanley, Michael J.
    Yeo, Karen Rowland
    Tugnait, Meera
    Iwasaki, Shinji
    Narasimhan, Narayana
    Zhang, Pingkuan
    Venkatakrishnan, Karthik
    Gupta, Neeraj
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2024, 13 (04): : 624 - 637
  • [26] Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug-Drug Interaction for Fesoterodine When Coadministered With Mirabegron
    Lin, Jian
    Goosen, Theunis C.
    Tse, Susanna
    Yamagami, Hidetomi
    Malhotra, Bimal
    JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 59 (11): : 1505 - 1518
  • [27] Physiologically based pharmacokinetic modeling of tacrolimus for food-drug and CYP3A drug-drug-gene interaction predictions
    Loer, Helena Leonie Hanae
    Feick, Denise
    Ruedesheim, Simeon
    Selzer, Dominik
    Schwab, Matthias
    Teutonico, Donato
    Frechen, Sebastian
    van Der Lee, Maaike
    Moes, Dirk Jan A. R.
    Swen, Jesse J.
    Lehr, Thorsten
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2023, 12 (05): : 724 - 738
  • [28] Physiologically based pharmacokinetic modeling of ponatinib to describe drug–drug interactions in patients with cancer
    Tomoko O. Morita
    Kazuhiko Hanada
    Cancer Chemotherapy and Pharmacology, 2022, 90 : 315 - 323
  • [29] Physiologically-Based Pharmacokinetic Modeling of Macitentan: Prediction of Drug-Drug Interactions
    de Kanter, Ruben
    Sidharta, Patricia N.
    Delahaye, Stphane
    Gnerre, Carmela
    Segrestaa, Jerome
    Buchmann, Stephan
    Kohl, Christopher
    Treiber, Alexander
    CLINICAL PHARMACOKINETICS, 2016, 55 (03) : 369 - 380
  • [30] Pharmacokinetic Drug–Drug Interaction of Apalutamide, Part 2: Investigating Interaction Potential Using a Physiologically Based Pharmacokinetic Model
    An Van den Bergh
    Jan Snoeys
    Loeckie De Zwart
    Peter Ward
    Angela Lopez-Gitlitz
    Daniele Ouellet
    Mario Monshouwer
    Caly Chien
    Clinical Pharmacokinetics, 2020, 59 : 1149 - 1160
12345